These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 24722266

  • 1. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
    Miao H, Choi BD, Suryadevara CM, Sanchez-Perez L, Yang S, De Leon G, Sayour EJ, McLendon R, Herndon JE, Healy P, Archer GE, Bigner DD, Johnson LA, Sampson JH.
    PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266
    [Abstract] [Full Text] [Related]

  • 2. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M, Sun R, Shi B, Wang Y, Di S, Luo H, Sun Y, Li Z, Zhou M, Jiang H.
    Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
    [Abstract] [Full Text] [Related]

  • 3. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
    O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV.
    Sci Transl Med; 2017 Jul 19; 9(399):. PubMed ID: 28724573
    [Abstract] [Full Text] [Related]

  • 4. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
    Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK, Herndon JE, Kuan CT, Morgan RA, Rosenberg SA, Johnson LA.
    Clin Cancer Res; 2014 Feb 15; 20(4):972-84. PubMed ID: 24352643
    [Abstract] [Full Text] [Related]

  • 5. Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.
    Ren PP, Li M, Li TF, Han SY.
    Curr Pharm Des; 2017 Feb 15; 23(14):2113-2116. PubMed ID: 28302023
    [Abstract] [Full Text] [Related]

  • 6. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
    Shen CJ, Yang YX, Han EQ, Cao N, Wang YF, Wang Y, Zhao YY, Zhao LM, Cui J, Gupta P, Wong AJ, Han SY.
    J Hematol Oncol; 2013 May 09; 6():33. PubMed ID: 23656794
    [Abstract] [Full Text] [Related]

  • 7. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
    Nakazawa T, Natsume A, Nishimura F, Morimoto T, Matsuda R, Nakamura M, Yamada S, Nakagawa I, Motoyama Y, Park YS, Tsujimura T, Wakabayashi T, Nakase H.
    Cells; 2020 Apr 16; 9(4):. PubMed ID: 32316275
    [Abstract] [Full Text] [Related]

  • 8. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
    Nehama D, Di Ianni N, Musio S, Du H, Patané M, Pollo B, Finocchiaro G, Park JJH, Dunn DE, Edwards DS, Damrauer JS, Hudson H, Floyd SR, Ferrone S, Savoldo B, Pellegatta S, Dotti G.
    EBioMedicine; 2019 Sep 16; 47():33-43. PubMed ID: 31466914
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer.
    Ohta K, Sakoda Y, Adachi K, Shinozaki T, Nakajima M, Yasuda H, Nagano H, Tamada K.
    Cancer Res Commun; 2024 Sep 01; 4(9):2514-2524. PubMed ID: 39240078
    [Abstract] [Full Text] [Related]

  • 10. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
    Müller N, Michen S, Tietze S, Töpfer K, Schulte A, Lamszus K, Schmitz M, Schackert G, Pastan I, Temme A.
    J Immunother; 2015 Jun 01; 38(5):197-210. PubMed ID: 25962108
    [Abstract] [Full Text] [Related]

  • 11. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE, Althani A, Afifi N, Hasan A, Caceci T, Pozzoli G, Cenciarelli C.
    Cancer Med; 2021 Aug 01; 10(15):5019-5030. PubMed ID: 34145792
    [Abstract] [Full Text] [Related]

  • 12. Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells.
    Murakami T, Nakazawa T, Natsume A, Nishimura F, Nakamura M, Matsuda R, Omoto K, Tanaka Y, Shida Y, Park YS, Motoyama Y, Nakagawa I, Yamada S, Tamura K, Takeshima Y, Takamura Y, Wakabayashi T, Nakase H.
    Anticancer Res; 2018 Sep 01; 38(9):5049-5056. PubMed ID: 30194149
    [Abstract] [Full Text] [Related]

  • 13. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H, Gao H, Kong J, Song B, Wang P, Shi B, Wang H, Li Z.
    Cancer Immunol Res; 2018 Nov 01; 6(11):1314-1326. PubMed ID: 30201736
    [Abstract] [Full Text] [Related]

  • 14. CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies.
    Agosti E, Garaba A, Antonietti S, Ius T, Fontanella MM, Zeppieri M, Panciani PP.
    Int J Mol Sci; 2024 Jun 29; 25(13):. PubMed ID: 39000281
    [Abstract] [Full Text] [Related]

  • 15. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
    Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, Fine HA, Rosenberg SA.
    J Immunother; 2019 May 29; 42(4):126-135. PubMed ID: 30882547
    [Abstract] [Full Text] [Related]

  • 16. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
    Li L, Zhu X, Qian Y, Yuan X, Ding Y, Hu D, He X, Wu Y.
    Front Immunol; 2020 May 29; 11():594271. PubMed ID: 33224149
    [Abstract] [Full Text] [Related]

  • 17. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J, Yan J, Liu B.
    Cancer Lett; 2017 Sep 10; 403():224-230. PubMed ID: 28649003
    [Abstract] [Full Text] [Related]

  • 18. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
    Brown CE, Aguilar B, Starr R, Yang X, Chang WC, Weng L, Chang B, Sarkissian A, Brito A, Sanchez JF, Ostberg JR, D'Apuzzo M, Badie B, Barish ME, Forman SJ.
    Mol Ther; 2018 Jan 03; 26(1):31-44. PubMed ID: 29103912
    [Abstract] [Full Text] [Related]

  • 19. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
    Sahin A, Sanchez C, Bullain S, Waterman P, Weissleder R, Carter BS.
    PLoS One; 2018 Jan 03; 13(7):e0199414. PubMed ID: 29975720
    [Abstract] [Full Text] [Related]

  • 20. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.
    Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, Zhang YJ, Baskin DS, Merchant FA, Brawley VS, Byrd TT, Krebs S, Wu MF, Liu H, Heslop HE, Gottschalk S, Yvon E, Ahmed N.
    Mol Ther; 2013 Nov 03; 21(11):2087-101. PubMed ID: 23939024
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.